The KBI Biopharma agreement provides that KBI Biopharma will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial...
Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02.
To acquire biologics manufacturing facility and capabilities from XOMAAcquires rights to Selexis cell line development technology. Purchases an exclusive license to a Phage Display library from Iontas
With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged.
JSR continues to demonstrate its commitment to the life sciences industry, by expanding its bioprocess capabilities and gaining a strong, successful partner.